http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107782896-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-365 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-543 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
filingDate | 2017-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2020-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2020-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-107782896-B |
titleOfInvention | Markers for breast cancer |
abstract | The invention relates to the field of biomedical detection, and provides a breast cancer marker. The markers include at least one of the following glycoproteins: serum transferrin having a terminal N-acetylglucosamine glycosyl, a plasma protease C1 inhibitory factor having a terminal N-acetylglucosamine glycosyl, and the serine protease inhibitor B4 having a terminal N-acetylglucosamine glycosyl. The amount of any one, two or all three of the three proteins in the sample to be detected is detected, so that the occurrence and/or the development of the breast cancer can be judged or assisted to be judged. The several/similar proteins can be used as a marker for breast cancer screening or auxiliary screening diagnosis singly or in any combination. |
priorityDate | 2017-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 811.